Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 3, 2007 - Issue 6
Submit an article Journal homepage
485
Views
49
CrossRef citations to date
0
Altmetric
Review

Drug transport across the placenta, role of the ABC drug efflux transporters

Javad Behravan University of Toronto, Department of Pharmaceutical Sciences, 144 College Street, Toronto, Ontario, M5S 3M2, Canada +1 416 946 3154; +1 416 978 8511; [email protected]; Mashhad University of Medical Sciences, Biotechnology Research Center, Faculty of Pharmacy, Mashhad, Iran
, PhD &
Micheline Piquette-Miller University of Toronto, Department of Pharmaceutical Sciences, 144 College Street, Toronto, Ontario, M5S 3M2, Canada +1 416 946 3154; +1 416 978 8511; [email protected]
, PhD
Pages 819-830 | Published online: 21 Nov 2007

Bibliography

  • MELETHIL S: Pharmacokinetics and pharmacodynamics of maternal-fetal transport of drugs of abuse: a critical review. NIDA Res. Monogr. (1995) 154:132-151.
  • HEWITT M, MADDEN JC, ROWE PH, CRONIN MT: Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier. SAR QSAR Environ. Res. (2007) 18(1-2):57-76.
  • DEREWLANY LO, LEEDER JS, KUMAR R et al.: The transport of digoxin across the perfused human placental lobule. J. Pharmacol. Exp. Ther. (1991) 256(3):1107-1111.
  • GEDEON C, BEHRAVAN J, KOREN G, PIQUETTE-MILLER M: Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta (2006) 27(11-12):1096-1102.
  • SASTRY BV: Techniques to study human placental transport. Adv. Drug Deliv. Rev. (1999) 38(1):17-39.
  • KRAEMER J, KLEIN J, LUBETSKY A, KOREN G: Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Am. J. Obstet. Gynecol. (2006) 195(1):270-274.
  • WATSON ED, CROSS JC: Development of structures and transport functions in the mouse placenta. Physiology (2005) 20:180-193.
  • USHIJIMA K, KIMURA A, INOKUCHI T et al.: Placental transport of bile acids: analysis of bile acids in maternal serum and urine, umbilical cord blood, and amniotic fluid. Kurume Med. J. (2001) 48(2):87-91.
  • ERICSSON A, HAMARK B, JANSSON N et al.: Hormonal regulation of glucose and system A amino acid transport in first trimester placental villous fragments. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 288(3):R656-R662.
  • YOUNG AM, ALLEN CE, AUDUS KL: Efflux transporters of the human placenta. Adv. Drug Deliv. Rev. (2003) 55(1):125-132.
  • SYME MR, PAXTON JW, KEELAN JA: Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. (2004) 43(8):487-514.
  • ST-PIERRE MV, SERRANO MA, MACIAS RI et al.: Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279(4):R1495-R1503.
  • BLACK RA, HILL DA: Over-the-counter medications in pregnancy. Am. Fam. Physician (2003) 67(12):2517-2524.
  • JACOBS LR: Prescription to over-the-counter drug reclassification. Am. Fam. Physician (1998) 57(9):2209-2214.
  • PETERS P, SCHAEFER CH: General comentary to drug therapy and drug risks in pregnancy. In: Drugs during Pregnancy and Lactation. Schaefer CH (Ed.), Elsevier, Amsterdam, The Netherlands (2001):1-13.
  • BONATI M, BORTOLUS R, MARCHETTI F, ROMERO M, TOGNONI G: Drug use in pregnancy: an overview of epidemiological (drug utilization) studies. Eur. J. Clin. Pharmacol. (1990) 38(4):325-328.
  • WARD SA, SEVENE EJ, HASTINGS IM, NOSTEN F, MCGREADY R: Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect. Dis. (2007) 7(2):136-144.
  • DELLICOUR S, HALL S, CHANDRAMOHAN D, GREENWOOD B: The safety of artemisinins during pregnancy: a pressing question. Malar. J. (2007) 6:15.
  • MATT DW, BORZELLECA JF: Toxic effects on the female reproductive system during pregnancy, parturition, and lactation. In: Reproductive Toxicology. Witorsch RJ (Ed.), Raven, New York (1995):175-193.
  • SASTRY BV: Placental toxicology: tobacco smoke, abused drugs, multiple chemical interactions, and placental function. Reprod. Fertil. Dev. (1991) 3(4):355-372.
  • WILSON JG: Current status of teratology. In: Handbook of Teratology. Wilson JG, Fraser FC (Eds), Plenum, New York, USA (1977):47.
  • ANNAS GJ, ELIAS S: Thalidomide and the titanic: reconstructing the technology tragedies of the twentieth century. Am. J. Public Health (1999) 89(1):98-101.
  • FARINE D: Challenges in drug use near term and during delivery. Can. J. Clin. Pharmacol. (2007) 14(1):E29-E33.
  • KOREN G: The way women perceive teratogenic risk. Can. J. Clin. Pharmacol. (2007) 14(1):E10-E16.
  • HALE EK, POMERANZ MK: Dermatologic agents during pregnancy and lactation: an update and clinical review. Int. J. Dermatol. (2002) 41(4):197-203.
  • FINKELSTEIN Y, REZVANI M, GARCIA-BOURNISSEN F, NURMOHAMED L, KOREN G: Inactive pharmaceutical ingredients: implications for pregnancy. Can. J. Clin. Pharmacol. (2007) 14(1):E17-E28.
  • DEMPSEY D, JACOB P III, BENOWITZ NL: Accelerated metabolism of nicotine and cotinine in pregnant smokers. J. Pharmacol. Exp. Ther. (2002) 301(2):594-598.
  • HEIKKINEN T, EKBLAD U, PALO P, LAINE K: Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin. Pharmacol. Ther. (2003) 73(4):330-337.
  • HEIKKINEN T, EKBLAD U, KERO P, EKBLAD S, LAINE K: Citalopram in pregnancy and lactation. Clin. Pharmacol. Ther. (2002) 72(2):184-191.
  • KOREN G, MACLEOD S, DAVIS D: Drugs in pregnancy: acknowledging challenges – finding solutions. Can. J. Clin. Pharmacol. (2007) 14(1):E2-E4.
  • MALEK A: Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine (2003) 21(24):3362-3364.
  • GEDEON C, KOREN G: Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta (2006) 27(8):861-868.
  • OLSEN GD: Placental permeability for drugs of abuse and their metabolites. NIDA Res. Monogr. (1995) 154:152-162.
  • TUZEL-KOX SN, PATEL HM, KOX WJ: Uptake of drug-carrier liposomes by placenta: transplacental delivery of drugs and nutrients. J. Pharmacol. Exp. Ther. (1995) 274(1):104-109.
  • BLOXAM DL, BAX CM, BAX BE: Culture of syncytiotrophoblast for the study of human placental transfer. Part I. Isolation and purification of cytotrophoblast. Placenta (1997) 18(2-3):93-98.
  • KOI H, ZHANG J, MAKRIGIANNAKIS A et al.: Syncytiotrophoblast is a barrier to maternal-fetal transmission of herpes simplex virus. Biol. Reprod. (2002) 67(5):1572-1579.
  • POWELL TL, LUNDQUIST C, DOUGHTY IM, GLAZIER JD, JANSSON T: Mechanisms of chloride transport across the syncytiotrophoblast basal membrane in the human placenta. Placenta (1998) 19(4):315-321.
  • CARIAPPA R, HEATH-MONNIG E, SMITH CH: Isoforms of amino acid transporters in placental syncytiotrophoblast: plasma membrane localization and potential role in maternal/fetal transport. Placenta (2003) 24(7):713-726.
  • HAY DL: Placental histology and the production of human choriogonadotrophin and its subunits in pregnancy. Br. J. Obstet. Gynaecol. (1988) 95(12):1268-1275.
  • KNIPP GT, AUDUS KL, SOARES MJ: Nutrient transport across the placenta. Adv. Drug Deliv. Rev. (1999) 38:41-48.
  • GADSBY JE, HEAP RB, BURTON RD: Oestrogen production by blastocyst and early embryonic tissue of various species. J. Reprod. Fertil. (1980) 60(2):409-417.
  • ENDERS AC, BLANKENSHIP TN: Comparative placental structure. Adv. Drug Deliv. Rev. (1999) 38(1):3-15.
  • NAGASHIGE M, USHIGOME F, KOYABU N et al.: Basal membrane localization of MRP1 in human placental trophoblast. Placenta (2003) 24(10):951-958.
  • MYLONA P, HOYLAND JA, SIBLEY CP: Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: no evidence for complementary expression. Placenta (1999) 20(5-6):493-496.
  • MEYER ZU SCHWABEDISSEN HE, GRUBE M, HEYDRICH B et al.: Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular differentiation. Am. J. Pathol. (2005) 166(1):39-48.
  • KITANO T, IIZASA H, HWANG IW et al.: Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the blood–placenta barrier. Biol. Pharm. Bull. (2004) 27(6):753-759.
  • BLOXAM DL: Human placental trophoblast culture: one-sided and two-sided models. Proc. Nutr. Soc. (1991) 50(2):349-354.
  • BLOXAM DL, BAX BE, BAX CM: Culture of syncytiotrophoblast for the study of human placental transfer. Part II. production, culture and use of syncytiotrophoblast. Placenta (1997) 18(2-3):99-108.
  • BOURGET P, ROULOT C, FERNANDEZ H: Transplacental transport and feto-placental metabolism of drugs: study methods, therapeutic contributions and implications. Therapie (1994) 49(6):481-497.
  • CRONIN MT: The use of in silico technologies to predict toxicity and fate: implementation and acceptance. Altex (2006) 23(Suppl.):365-368.
  • CHANG C, EKINS S, BAHADDURI P, SWAAN PW: Pharmacophore-based discovery of ligands for drug transporters. Adv. Drug Deliv. Rev. (2006) 58(12-13):1431-1450.
  • CHANG C, BAHADDURI PM, POLLI JE, SWAAN PW, EKINS S: Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab. Dispos. (2006) 34(12):1976-1984.
  • GROS P, BEN NERIAH YB, CROOP JM, HOUSMAN DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature (1986) 323(6090):728-731.
  • DEVAULT A, GROS P: Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell Biol. (1990) 10(4):1652-1663.
  • JULIANO RL, LING V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta (1976) 455(1):152-162.
  • TANABE M, IEIRI I, NAGATA N et al.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297(3):1137-1143.
  • THIEBAUT F, TSURUO T, HAMADA H et al.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. USA (1987) 84(21):7735-7738.
  • BENDAYAN R, LEE G, BENDAYAN M: Functional expression and localization of P-glycoprotein at the blood–brain barrier. Microsc. Res. Tech. (2002) 57(5):365-380.
  • VIRGINTINO D, ROBERTSON D, ERREDE M et al.: Expression of P-glycoprotein in human cerebral cortex microvessels. J. Histochem. Cytochem. (2002) 50(12):1671-1676.
  • MATHIAS AA, HITTI J, UNADKAT JD: P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289(4):R963-R969.
  • ATKINSON DE, GREENWOOD SL, SIBLEY CP, GLAZIER JD, FAIRBAIRN LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am. J. Physiol. Cell Physiol. (2003) 285(3):C584-C591.
  • BORST P, ELFERINK RO: Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. (2002) 71:537-592.
  • SCHINKEL AH, MAYER U, WAGENAAR E et al.: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA (1997) 94(8):4028-4033.
  • LANKAS GR, WISE LD, CARTWRIGHT ME, PIPPERT T, UMBENHAUER DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. (1998) 12(4):457-463.
  • LANKAS GR, CARTWRIGHT ME, UMBENHAUER D: P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. (1997) 143(2):357-365.
  • SCHINKEL AH, SMIT JJ, VAN TELLINGEN O et al.: Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell (1994) 77(4):491-502.
  • SCHINKEL AH, MOL CA, WAGENAAR E et al.: Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer (1995) 31A(7-8):1295-1298.
  • SMIT JW, HUISMAN MT, VAN TELLINGEN O, WILTSHIRE HR, SCHINKEL AH: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. (1999) 104(10):1441-1447.
  • USHIGOME F, TAKANAGA H, MATSUO H et al.: Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. (2000) 408(1):1-10.
  • SAMTANI MN, SCHWAB M, NATHANIELSZ PW, JUSKO WJ: Area/moment and compartmental modeling of pharmacokinetics during pregnancy: applications to maternal/fetal exposures to corticosteroids in sheep and rats. Pharm. Res. (2004) 21(12):2279-2292.
  • GOH BC, LEE SC, WANG LZ et al.: Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. (2002) 20(17):3683-3690.
  • SCHUETZ EG, FURUYA KN, SCHUETZ JD: Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. (1995) 275(2):1011-1018.
  • PIQUETTE-MILLER M, GRANT DM: The art and science of personalized medicine. Clin. Pharmacol. Ther. (2007) 81(3):311-315.
  • FROMM MF: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. (2002) 54(10):1295-1310.
  • KRUH GD, BELINSKY MG: The MRP family of drug efflux pumps. Oncogene (2003) 22(47):7537-7552.
  • MAHER JM, SLITT AL, CHERRINGTON NJ, CHENG X, KLAASSEN CD: Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice. Drug Metab. Dispos. (2005) 33(7):947-955.
  • COLE SP, BHARDWAJ G, GERLACH JH et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 258(5088):1650-1654.
  • LESLIE EM, DEELEY RG, COLE SP: Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. (2005) 204(3):216-237.
  • HOOIJBERG JH, JANSEN G, ASSARAF YG et al.: Folate concentration dependent transport activity of the multidrug resistance protein 1 (ABCC1). Biochem. Pharmacol. (2004) 67(8):1541-1548.
  • IFERGAN I, SHAFRAN A, JANSEN G et al.: Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J. Biol. Chem. (2004) 279(24):25527-25534.
  • KEPPLER D, JEDLITSCHKY G, LEIER I: Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol. (1998) 292:607-616.
  • JEDLITSCHKY G, LEIER I, BUCHHOLZ U et al.: ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem. J. (1997) 327(Part 1):305-310.
  • LESLIE EM, HAIMEUR A, WAALKES MP: Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. (2004) 279(31):32700-32708.
  • LESLIE EM, DEELEY RG, COLE SP: Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology (2001) 167(1):3-23.
  • KARTENBECK J, LEUSCHNER U, MAYER R, KEPPLER D: Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin–Johnson syndrome. Hepatology (1996) 23(5):1061-1066.
  • PAULUSMA CC, KOOL M, BOSMA PJ et al.: A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 25(6):1539-1542.
  • PAULUSMA CC, OUDE ELFERINK RP: The canalicular multispecific organic anion transporter and conjugated hyperbilirubinemia in rat and man. J. Mol. Med. (1997) 75(6):420-428.
  • MEYER ZU SCHWABEDISSEN HE, JEDLITSCHKY G, GRATZ M et al.: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab. Dispos. (2005) 33(7):896-904.
  • BORST P, EVERS R, KOOL M, WIJNHOLDS J: A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. (2000) 92(16):1295-1302.
  • HAIMEUR A, CONSEIL G, DEELEY RG, COLE SP: The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. (2004) 5(1):21-53.
  • HIROHASHI T, SUZUKI H, SUGIYAMA Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J. Biol. Chem. (1999) 274(21):15181-15185.
  • ZENG H, LIU G, REA PA, KRUH GD: Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res. (2000) 60(17):4779-4784.
  • SCHEFFER GL, KOOL M, DE HAAS M et al.: Tissue distribution and induction of human multidrug resistant protein 3. Lab. Invest. (2002) 82(2):193-201.
  • KOOL M, VAN DER LINDEN M, DE HAAS M et al.: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA (1999) 96(12):6914-6919.
  • YOUNG LC, CAMPLING BG, VOSKOGLOU-NOMIKOS T et al.: Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res. (1999) 5(3):673-680.
  • YOUNG LC, CAMPLING BG, COLE SP, DEELEY RG, GERLACH JH: Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin. Cancer Res. (2001) 7(6):1798-1804.
  • WIELINGA PR, REID G, CHALLA EE et al.: Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol. Pharmacol. (2002) 62(6):1321-1331.
  • WIJNHOLDS J, MOL CA, VAN DEEMTER L et al.: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc. Natl. Acad. Sci. USA (2000) 97(13):7476-7481.
  • BAI J, LAI L, YEO HC, GOH BC, TAN TM: Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int. J. Biochem. Cell Biol. (2004) 36(2):247-257.
  • LAI L, TAN TM: Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem. J. (2002) 361(Part 3):497-503.
  • HOPPER E, BELINSKY MG, ZENG H et al.: Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett. (2001) 162(2):181-191.
  • HOPPER-BORGE E, CHEN ZS, SHCHAVELEVA I, BELINSKY MG, KRUH GD: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res. (2004) 64(14):4927-4930.
  • DOYLE LA, YANG W, ABRUZZO LV et al.: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA (1998) 95(26):15665-15670.
  • DOYLE LA, ROSS DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene (2003) 22(47):7340-7358.
  • ALLEN JD, SCHINKEL AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. (2002) 1(6):427-434.
  • XU J, LIU Y, YANG Y, BATES S, ZHANG JT: Characterization of oligomeric human half-ABC transporter ATP-binding cassette G2. J. Biol. Chem. (2004) 279(19):19781-19789.
  • MALIEPAARD M, SCHEFFER GL, FANEYTE IF et al.: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. (2001) 61(8):3458-3464.
  • KRISHNAMURTHY P, ROSS DD, NAKANISHI T et al.: The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. (2004) 279(23):24218-24225.
  • ZHOU S, MORRIS JJ, BARNES Y et al.: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc. Natl. Acad. Sci. USA (2002) 99(19):12339-12344.
  • JONKER JW, SMIT JW, BRINKHUIS RF et al.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. (2000) 92(20):1651-1656.
  • GIL S, SAURA R, FORESTIER F, FARINOTTI R: P-glycoprotein expression of the human placenta during pregnancy. Placenta (2005) 26(2-3):268-270.
  • MACFARLAND A, ABRAMOVICH DR, EWEN SW, PEARSON CK: Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. (1994) 26(5):417-423.
  • VAN KALKEN C, GIACCONE G, VAN DER VALK P et al.: Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am. J. Pathol. (1992) 141(5):1063-1072.
  • PASCOLO L, FERNETTI C, PIRULLI D et al.: Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochem. Biophys. Res. Commun. (2003) 303(1):259-265.
  • YEBOAH D, SUN M, KINGDOM J et al.: Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and term before and after labor. Can. J. Physiol. Pharmacol. (2006) 84(12):1251-1258.
  • WANG H, WU X, HUDKINS K et al.: Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptors. Am. J. Physiol. Endocrinol. Metab. (2006) 291(6):E1295-E1304.
  • YASUDA S, ITAGAKI S, HIRANO T, ISEKI K: Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation. Biosci. Biotechnol. Biochem. (2005) 69(10):1871-1876.
  • WANG JH, SCOLLARD DA, TENG S, REILLY RM, PIQUETTE-MILLER M: Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J. Nucl. Med. (2005) 46(9):1537-1545.
  • CHEN YH, WANG JP, WANG H et al.: Lipopolysaccharide treatment downregulates the expression of the pregnane X receptor, cyp3a11 and mdr1a genes in mouse placenta. Toxicology (2005) 211(3):242-252.
  • WANG JS, TENG S, PIQUETTE-MILLER M: Effect of maternal inflammation on the expression of ABCB1 and ABCG2 in placenta. Clin. Pharmacol. Ther. (2006) 79:P5.
  • SHAARAWY M, NAGUI AR: Enhanced expression of cytokines may play a fundamental role in the mechanisms of immunologically mediated recurrent spontaneous abortion. Acta Obstet. Gynecol. Scand. (1997) 76(3):205-211.
  • KIRWAN JP, HAUGUEL-DE MOUZON S, LEPERCQ J et al.: TNF-α is a predictor of insulin resistance in human pregnancy. Diabetes (2002) 51(7):2207-2213.
  • HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97(7):3473-3478.
  • KOBAYASHI D, IEIRI I, HIROTA T et al.: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. (2005) 33(1):94-101.
  • KALABIS GM, KOSTAKI A, ANDREWS MH et al.: Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection. Biol. Reprod. (2005) 73(4):591-597.
  • JANCIS EM, CARBONE R, LOECHNER KJ, DANNIES PS: Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells. Mol. Pharmacol. (1993) 43(1):51-56.
  • JANCIS EM, CHEN HX, CARBONE R, HOCHBERG RB, DANNIES PS: Rapid stimulation of rhodamine 123 efflux from multidrug-resistant KB cells by progesterone. Biochem. Pharmacol. (1993) 46(9):1613-1619.
  • PIEKARZ RL, COHEN D, HORWITZ SB: Progesterone regulates the murine multidrug resistance mdr1b gene. J. Biol. Chem. (1993) 268(11):7613-7616.
  • MUTOH K, TSUKAHARA S, MITSUHASHI J, KATAYAMA K, SUGIMOTO Y: Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci. (2006) 97(11):1198-1204.
  • KALABIS GM, PETROPOULOS S, GIBB W, MATTHEWS SG: Breast cancer resistance protein (bcrp1/abcg2) in mouse placenta and yolk sac: ontogeny and its regulation by progesterone. Placenta (2007) 28(10):1073-1081.
  • TEODORI E, DEI S, MARTELLI C, SCAPECCHI S, GUALTIERI F: The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets (2006) 7(7):893-909.
  • ITO S: Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin. Perinatol. (2001) 25(3):196-201.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.